VolitionRx (VNRX) surges 10.71% premarket after securing $2.0 million in funding.

VolitionRx surged 10.71% in premarket trading following the announcement that it scheduled its Second Quarter 2025 Earnings Conference Call and Business Update on August 8, 2025. The move coincided with positive investor sentiment driven by recent developments, including the company’s inclusion of its Nu.Q® NETs Assay in France’s sepsis early-detection evaluation and breakthrough clinical data for its veterinary cancer test. Additionally, insider buying activity on August 7, 2025, where a director acquired $50,000 in stock, further reinforced confidence. The premarket rally reflects anticipation of operational progress and strategic partnerships highlighted in the upcoming business update.